1Bast R.King,St John E.A radioimmuncassay,using a mon-oclonal antibody to monitor the course of epithelial ovarian cancer[J].N Ergl J Med,1983,309(3):169.
2Crump C,McIntosh MW,Urban IV,et al.Ovarian cancer tumor marker behador is asymptomatic healthy woman:implica-fions for scrcening[J].Cancer Epidemoiol Biomarkers Prev,2000,9(10):1107.
3Stifling D,Evans DG,Pichert G,et al.Surecning for familialovarian cancer:failure of current protocols to detect ovarian canc-er at an early stage according to the international federation of gyecology and obstetrics system[J].J Clin Oncol,2005,23(24):5443.
4Menon V,Skates SJ,Lewis S,et al.Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer[J].J Clin Oncol,2005,23(31):7919.
6Deify MJ,onfrer JM,Kulpa J,et al.CA125 in ovarian canc-er:European group on tumor markers guidelines for clinical use[J].Int J Gynecol Cancer,2005,15(4):679.
7ParamasivaR S,Tripcony L,Crandom A,et al.Prognostic importance of preoperative CA-125 in international federation of gynecology and obsrevics stage I epithelial ovarian cancer:an Australian muhicenter study[J].J Chin Oncol,2005,23(25):5938.
8Saygili V,Guclu S,Uslu T,et al.The effect of ascites,mass,volume,and peritoneal carcinomatosis on serum CA125 lev-els is patients with ovarian carcinoma[J].Int J Gynocol Cancer,2002,12(3):438.
9Chi DS,Venkatraman ES,Masson,et al.The ability of pre-oparative serrum CA125 to predict optimal primary tumor cytore-duction in stage Ⅲ epithelial ovarian carcinoma[J].Cyneol On-col,2000,77(2):227.
10Santi Van Antonio,Gary R,Zahurak ML.Risk of epithelial ovarian cancer recurrence in patients with rising serum CA125 lev-els with the normal range[J].J Clin Onol,2005,23(36):9338.
二级参考文献20
1Liu LY. Relationship between serum CA125 level and second-look findings in ovarian cancers. Zhonghua Zhongliu Zazhi,1992,14(4):287-289.
2Sugiyama T, Nishida T, Komai K, et al. Comparison of CA125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer. Int J Gynaecol Obstet,1996,54(3) :251-256.
3SantiUan Antonio, Garg R, Zahurak ML. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA125 levels with the normal range. J Clin Oncol, 2005,23 (36) : 9338-9343.
4Geisler JP, Miller GA, Lee TH, et al. Relationship of preoperative serum CA125 to survival in epithelial ovarian carcinoma. J Reprod Med, 1996,41(3) :140-142.
5Hunter VJ, Daly L, Helms M, et al. The prognostie significance of CA125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol, 1990,163 : 1164.
6Markman M, Federieo M, Liu PY, et al. Significance of early changes in the serum CA125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol, 2006, 2 ( Epub ahead of print).
7Markman M, Liu PY, Pothenberg ML, et al. Pretreatment CA125 and risk of relapse in advanced cancer. J Clin Oncol, 2006,24 (9) :1454-1458.
8O' Brien TJ, Tanimoto H, Konishi I, et al. More than 15 years of CA125:what is known about the antigen,its strueture and its function. Int J Biol Marker, 1998,13(4) : 188-195.
9Bon GG, Kenemans P, Verstraeten R, et al. Serum tumor marker immunoassays in gynaecologic ontology: establishment of reference values. Am J Obstet Gynecol, 1996,174 : 107-114.
10Crump C, Melntosh MW, Urban N, et al. Ovarian cancer tumor marker behavior in asymptomatic healthy woman :implications for screening, Cancer Epidemiol Biornrkets Prey,2000,9(10) :1107-1111.
